Drug
Remdesivir placebo
Remdesivir placebo is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
4
100%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Suspended1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 34 (100.0%)
Trials by Status
suspended125%
terminated125%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04843761
completedphase_3
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT06729593
terminatedphase_3
A Trial of Remdesivir in Adults With Severe COVID-19
NCT04257656
suspendedphase_3
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
NCT04252664
Clinical Trials (4)
Showing 4 of 4 trials
NCT04843761Phase 3
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT06729593Phase 3
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT04257656Phase 3
A Trial of Remdesivir in Adults With Severe COVID-19
NCT04252664Phase 3
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4